💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Zoledronic Acid

CHEMBL4303669 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
272.1 g/mol
LogP
-4.3
Phase
4

This bisphosphonate medication is given as an annual or more frequent intravenous infusion to treat osteoporosis and prevent bone fractures, and is also used to treat elevated calcium caused by cancer, bone complications from multiple myeloma, and bone metastases from solid tumors. It works by attaching to bone surfaces and blocking the cells (osteoclasts) that break down bone, preserving bone density. Flu-like symptoms are common after the first infusion, and a rare but serious complication is osteonecrosis of the jaw, particularly in cancer patients.

Khối lượng phân tử

272,0900 g/mol

LogP

-4,30

TPSA

153,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Age-Related Macular Degeneration Pain Management Non-Small Cell Lung Cancer Osteoporosis Parkinson's Disease Oncology Multiple Sclerosis Stroke Lymphoma Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O.O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C5H10N2O7P2

                    

                    
                    

                        
HBD / HBA

                        
5 / 8

                    

                    
                    

                        
Liên kết có thể quay

                        
4

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
16

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
This bisphosphonate medication is given as an annual or more frequent intravenous infusion to treat osteoporosis and prevent bone fractures, and is also used to treat elevated calcium caused by cancer, bone complications from multiple myeloma, and bone metastases from solid tumors. It works by attaching to bone surfaces and blocking the cells (osteoclasts) that break down bone, preserving bone density. Flu-like symptoms are common after the first infusion, and a rare but serious complication is osteonecrosis of the jaw, …

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Zoledronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4303669.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 68740.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.